1. India Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Titan Biotech Limited

Titan Biotech Limited

BBSE:TITANBIO
325.85
INR
-7.87
(-2.36%)
8.04EPS
38.07P/E
16.13BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
11.12
10.42
11.83
13.62
14.83
15.71
19.23
34.42
29.9
34.85
39.71
37.86
49.9
53
Basic EPS, GAAP
0.42
0.42
0.46
0.56
0.66
0.85
1.71
7.34
5.25
6.01
6.01
5.21
7.23
8.2
Free Cash Flow per Basic Share
-0.59
-0.9
0.05
-1.82
-1
0.25
0.16
3.44
2.02
1.87
0.35
2.8
5.56
- -
Dividend per Share
0.18
0.18
0.18
0.18
0.18
- -
- -
0.2
0.3
0.3
0.36
0.4
0.4
- -
Book Value per Share
4.36
5.29
5.56
5.95
6.29
7.79
9.49
16.64
19.24
26.6
32.3
37.13
43.94
- -
Tangible Book Value per Share
4.36
5.29
5.56
5.89
6.25
7.76
9.46
16.62
19.22
26.58
32.28
37.1
43.92
- -
Basic Weighted Avg Shares
35
39
39
39
39
41
41
41
41
41
41
41
41
41
Sales/Revenue/Turnover
391
403
458
527
574
649
794
1,422
1,235
1,440
1,641
1,565
2,062
2,189
Operating Margin (%)
6.03
7.58
6.88
8.79
10.55
11.39
14.78
31.2
23.39
18.75
18.86
13.59
16.51
17
Depreciation Expense
8
8
8
8
9
17
18
22
24
26
33
42
49
51
Net Income, GAAP
15
16
18
22
25
35
71
303
217
248
249
215
299
339
Effective Tax Rate (%)
33.22
33.39
33.31
34.87
34.92
29.43
24.67
25.76
25.15
25.22
24.95
25.02
28.1
28.17
Profit Margin (%)
3.81
4.05
3.86
4.14
4.43
5.43
8.89
21.33
17.55
17.25
15.15
13.76
14.49
15.48
Working Capital
81
108
111
173
183
194
238
395
468
480
530
618
593
- -
LT Debt
39
22
43
152
179
132
116
63
22
14
11
4
18
- -
Total Equity
153
205
227
241
255
338
415
725
862
1,099
1,335
1,534
1,815
- -
Return on Invested Capital (%)
7.43
8.03
6.72
7.38
8.04
9.31
14.97
42.03
23.42
18.71
17.85
10.7
14
- -
Return on Capital (%)
8.17
8.72
7.24
7.53
7.91
8.58
12.78
39.38
20.81
23.66
19.65
14.75
17.71
- -
Return on Common Equity (%)
10.01
9.11
8.42
9.79
10.74
12.46
19.8
56.2
29.25
26.23
20.42
15.01
17.84
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
39
- -
LT Borrowings
- -
3
- -
LT Finance Leases
- -
14
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
52
41
52
Market Capitalization
8,708
15,129
16,131

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
852
- -
Cash, Cash Equivalents & STI
- -
19
- -
Accounts Receivable, Net
- -
228
- -
Inventories
- -
558
- -
Total Current Liabilities
- -
260
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
39
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.32%
20.23%
18.35%
Free Cash Flow
-147.66%
132.44%
98.97%
Net Income, GAAP
51.99%
2.31%
38.8%
Sales/Revenue/Turnover
18.31%
8.9%
31.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
431
399
383
352
1,565
2026
465
544
565
488
2,062
2027
592
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.55
1.62
1.06
0.98
5.21
2026
1.66
1.88
2.06
1.63
7.23
2027
2.63
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.4
2026
- -
- -
- -
- -
0.4
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Naresh Kumar Singla
Full Time Employees
527
Sector
Health technology
Industry
Biotechnology
Address
903-909, Bigjos Tower New Delhi DE India 110034
IPO Date
Nov 30, 2000
Website
titanbiotechltd.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Titan Biotech Limited is a New Delhi-based public Indian biotechnology company established in 1992 that manufactures and exports a broad range of biological products for multiple industries. Its core product portfolio includes protein hydrolysates, peptones, malt extract, yeast extract, liver extract, bile extract and derivatives, dehydrated culture media and media bases, laboratory chemicals, plant tissue culture media, plant growth promoters, and essential ingredients for soil nutrition and food additives. These products serve pharmaceutical, nutraceutical, food and beverage, biotechnology and fermentation, cosmetic, veterinary and animal feed, and agriculture industry applications. Titan Biotech's offerings also extend to active pharmaceutical ingredients (APIs), biologics, nutraceuticals, and specialty additives. The company operates internationally, with a market presence in over 100 countries, showcasing a robust export business. In the last 1-2 years, Titan Biotech has expanded its product range by launching new biologically derived products such as a latest range of prebiotics and enzymes targeting nutritional and feed supplement markets. It has also made strategic acquisitions, notably increasing its stake in Titan Media Ltd. to 64.58% in early 2024, enhancing its production and product diversification capabilities. The company is actively engaged in research and development to innovate in biotechnology and related fields. Additionally, Titan Biotech strengthened its industry collaborations, including recent corporate partnerships emphasizing hair care ingredient development and aquaculture nutrition support. Titan Biotech Limited is ISO 9001:2008 certified and cGMP facilitated, underscoring its commitment to quality in manufacturing. It serves a diverse customer base across pharmaceutical, food processing, veterinary, agricultural sectors, and scientific research institutions. The company has two manufacturing facilities based in Bhiwadi, Rajasthan, India, and maintains registrations with relevant regulatory bodies including FSSAI for food-grade products. Titan Biotech’s ongoing efforts focus on introducing new bioactive ingredients, expanding its global footprint, and reinforcing its position as a key supplier of biopharmaceutical and biotechnological products.